Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Oncorus
company
About
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $57M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Apr 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$136.50M
Oncorus has raised a total of
$136.50M
in funding over 2 rounds. Their latest funding was raised on
Aug 21, 2019 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 21, 2019 | Series B | $79.50M | 2 | — | — | Detail |
| Jul 19, 2016 | Series A | $57M | 3 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
5
Oncorus is funded by 5 investors.
Shinhan Private Equity
and UBS Oncology Impact Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Shinhan Private Equity
|
— | Series B |
|
|
— | Series B |
|
|
— | Series A |
|
|
— | Series A |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
